NewsBIO USA 2024 참석

June 11, 20240
NEWS | June, 2024BIO USA 2024 참석
BIO USA 2024

차세대 세포치료제 선도기업인 카리스바이오는 BIO USA 2024에 참가하여 글로벌 제약기업들과 파트너쉽 프로그램을 진행하였습니다. 윤영섭 대표이사는 이번 행사 기간 중 한국보건산업진흥원이 주관한 ‘K-Blockbuster Company Showcase’에 초청되어 유도만능줄기세포 유래 내피세포(iPSC-EC) 기반 심혈관치료제에 대해 발표하였으며, 글로벌 파트너쉽 확대를 통한 기업 성장 전략을 밝혔습니다.

한편, 카리스바이오는 이번 4월에 유도만능줄기세포 제제를 이용한 세포치료제로서는 한국 최초, 혈관내피세포를 이용한 세계 최초의 임상시험을 승인받았습니다.


KarisBio, a leading next-generation cell therapy company, participated in BIO USA 2024 and engaged in partnership programs with global pharmaceutical companies. During the event, CEO Young-sup Yoon was invited to the ‘K-Blockbuster Company Showcase’ organized by the Korea Health Industry Development Institute, where he presented on the cardiovascular therapy based on induced pluripotent stem cell-derived endothelial cells (iPSC-EC) and revealed the company’s strategic plans for growth through the expansion of global partnerships.

Meanwhile, in April, Karisbio received approval for the world’s first clinical trial using endothelial cells and Korea’s first cell therapy product using induced pluripotent stem cell preparations.

Leave a Reply

Your email address will not be published. Required fields are marked *